



RAPID ALERT

DRAP ALERT No: N° I/S/04-25-36

CRACKDOWN AGAINST FALSIFIED / SPURIOUS DRUGS

Date: 15th April, 2025

Target Audience:

- Regulatory Field Force of DRAP and Provincial Drug Control departments.
- Healthcare Professionals
- Pharmacies and medical stores

Problem Statement:

Directorate of Drug Control Punjab (DDCP) has informed Drug Regulatory Authority of Pakistan that the sample of below mentioned product has been declared '*Spurious*'. The detail of report is as under:

S#	Product Name	Batch No.	Purported Manufacturer	Remarks
1.	GABICA Capsule Each capsule contains: Pregabalin.....300mg	399C27	M/s Getz Pharma (Pvt) Ltd., 29-30/27 , Korangi Industrial Area, Karachi.	'Substandard' with regards to Assay and Dissolution, ' Spurious ' as per Section 3(z-b) (ii) and ' Adulterated ' as per Section 3(a)(v) of Drugs Act, 1976.

Risk Statement:

Falsified products having no active ingredient or identification of manufacturer pose a great risk to the health of patient and can cause adverse drug reactions or may lead to therapy failure that can result in fatal consequences.

Action Initiated: -

The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.

Advice for Healthcare Professionals: -

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of the product should be reported to National or Provincial pharmacovigilance centers using [Adverse Event Reporting Form](#) or online through this [link](#). Further information on reporting problems to DRAP is available on this [link](#).



DRAP, Islamabad

+ 92 051 9255969

gsms@dra.gov.pk



Comparison of Original and Falsified products:

Parameters	Sample taken by Drug Inspector (Batch No. 399C27)	QC retention sample from Manufacturer (Batch No. 399C27)
Outer Carton	Pattern and font style of product details such as Batch No., Price, manufacturing and Expiry dates (e.g Digits '0,3,9,7,6 and 4') is different as compared to the QC retention sample.	Pattern and font style of product details such as Batch No., Price, manufacturing and Expiry dates (e.g Digits '0,3,9,7,6 and 4') is different as compared to the given sample.
Blister strip	Batch No. and expiry date is unreadable as well as on left alignment as compared with the QC retention sample.	Batch No. and expiry date is readable as well as on right alignment as compared with the given sample.
Capsule	<ul style="list-style-type: none">• Getz logo is misprinted in case of given sample.• Getz logo is printed on body, while '300mg' is printed on cap in case of given sample.	<ul style="list-style-type: none">• Getz Logo is clearly printed in case of QC retention sample.• Getz Logo is printed on cap, while '300mg' is printed on body in case of QC retention sample.

Advice for Consumers:

Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned product and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre.

All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.



Drug Regulatory Authority of Pakistan

محفوظ، موثر اور معیاری اشیائے علاج

